News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oragenics, Inc. (OGEN) Advances Towards Identification Of Lead Antibiotic Clinical Candidate



5/6/2014 8:08:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE: XON), a leader in synthetic biology, it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 (MU1140) lantibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES